Table 1. Baseline characteristics of patients and study periods.
| Period | ||||||
|---|---|---|---|---|---|---|
| total | 1997–2000 | 2001–2004 | 2005–2008 | 2009–2012 | p | |
| N (%) | 189 (100) | 28 (14.8) | 42 (22.2) | 55 (29.1) | 64 (33.9) | |
| Gender* | 0.011 | |||||
| Male | 175 (92.6) | 26 (92.9) | 34 (81) | 53 (96.4) | 62 (96.9) | |
| Female | 14 (7.4) | 2 (7.1) | 8 (19) | 2 (3.6) | 2 (3.1) | |
| Age** (n = 188) | 33 (28–39) | 30 (26–36) | 31 (27–37) | 34 (28–38) | 34 (27–39) | 0.275 |
| <30* | 63 (33.5) | 13 (46.4) | 16 (38.1) | 14 (25.5) | 20 (31.7) | |
| 30–40 | 82 (43.6) | 10 (35.7) | 20 (47.6) | 27 (49.1) | 25 (39.7) | |
| 40–50 | 33 (17.6) | 3 (10.7) | 4 (9.5) | 12 (21.8) | 14 (22.2) | |
| >50 | 10 (5.3) | 2 (7.1) | 2 (4.8) | 2 (3.6) | 4 (6.3) | |
| Route of transmission* | 0.004 | |||||
| MSM-bisexual | 153 (81) | 21 (75) | 30 (71.4) | 47 (85.5) | 55 (85.9) | |
| Heterosexual | 21 (11.1) | 2 (7.1) | 8 (19) | 6 (10.9) | 5 (7.8) | |
| IDU | 10 (5.3) | 5 (17.9) | 4 (9.5) | 1 (1.8) | 0 (0) | |
| Unknown | 5 (2.6) | 0 (0) | 0 (0) | 1 (0) | 4 (6.3) | |
| Origin* | 0.052 | |||||
| Native | 120 (63.5) | 24 (85.7) | 24 (57.1) | 36 (65.5) | 36 (56.3) | |
| Immigrant | 59 (31.2) | 2 (7.1) | 14 (33.3) | 18 (32.7) | 25 (39.1) | |
| Unknown | 10 (5.3) | 2 (7.1) | 4 (9.5) | 1 (1.8) | 3 (4.7) | |
| Symptomatic* | 0.626 | |||||
| yes | 162 (85.7) | 23 (82.1) | 34 (81) | 49 (89.1) | 56 (87.5) | |
| no | 27 (14.3) | 5 (17.9) | 8 (19) | 6 (10.9) | 8 (12.5) | |
| Plasma HIV-1 log10RNA** (n = 188) | 5.17 (4.51–5.80) | 5.04 (4.39–5.80) | 5 (4.43–5.40) | 5.45 (4.75–5.62) | 5.41 (4.50–5.89) | 0.168 |
| <5.0* | 78 (41.5) | 13 (46.4) | 21 (50) | 19 (35.2) | 25 (39.1) | |
| >5.0 | 110 (58.5) | 15 (53.6) | 21 (50) | 35 (64.8) | 39 (60.9) | |
| CD4 cell count/ul** (n = 188) | 494 (375–619) | 494 (376–637) | 584 (438–740) | 506 (377–618) | 402 (309–562) | 0.009 |
| <350 | 45 (23.9) | 6 (21.4) | 8 (19) | 10 (18.5) | 21 (32.8) | |
| 350–500 | 52 (27.7) | 8 (28.6) | 8 (19) | 15 (27.8) | 21 (32.8) | |
| >500 | 91 (48.4) | 14 (50) | 26 (61.9) | 29 (53.7) | 22 (34.4) | |
| Acute or Recent infection at genotyping* | 0.21 | |||||
| Acute (infection of <30 days) | 23 (12.2) | 2 (7.2) | 1 (2.4) | 9 (16.4) | 11 (17.2) | |
| Recent (infection between 30 and 180 days) | 166 (87.8) | 26 (92.8) | 41 (97.6) | 46 (83.6) | 53 (82.8) | |
| Resistant strain (any mutation)* | 17 (9) | 5 (17.9) | 4 (9.5) | 2 (3.6) | 6 (9.4) | 0.2 |
| Non-B subtypes* | 20 (10.6) | 0 (0) | 2 (4.8) | 5 (9.1) | 13 (20.3) | 0.01 |
* n(%)
** median (IQR)
MSM: men-who-have-sex-with-men
IDU: injective drug user